Press releases/news

The Naveni in situ Proximity Ligation Assay technique will be provided by the SciLifeLab unit Affinity Proteomics Uppsala

Scilife

Uppsala 05/10-2021

Navinci Diagnostics AB and Science for Life Laboratory, SciLifeLab, have entered a collaboration where the Naveni in situ Proximity Ligation Assay technique will be provided by the SciLifeLab unit Affinity Proteomics Uppsala

”We are delighted to partner with SciLifeLab and the Affinity Proteomics unit in Uppsala, as this allows the NaveniTM in situ proximity ligation assay technology to support the mission of SciLifeLab to enable life science research in Sweden to provide access to the latest key technologies. This collaboration will significantly benefit our academic customers that need help with assay development or sample analysis to support their research on protein interactions or signaling pathways. This is a natural continuation of the long-lasting close collaboration between Uppsala University, SciLifeLab, and Navinci.”
Robert Gunnarsson, CEO Navinci Diagnostics AB

”By implementing Navinci’s innovative products, we will be able to further strengthen our offering of in situ proximity ligation assay services by highly sensitive and reproducible assays. We are happy to continue a local and close relationship with companies with a legacy from Uppsala University.”
Mikael Åberg, Head of Affinity Proteomics Uppsala, SciLifeLab.

Founded upon the research by Ulf Landegren and colleagues at Uppsala University, Navinci (formerly known as Olink Bioscience) is a Swedish life science company that develops and markets in situ proximity ligation assays to monitor proteins, their interactions, and modifications. The technology provides an essential tool for spatial biology and reveals the responses to disease and drug treatment directly in the tissue microenvironment.
SciLifeLab leverages the unique strengths of individual researchers across Sweden into a focused resource for the life science community. SciLifeLab provides access for thousands of researchers to the cutting-edge instrumentation and deep scientific expertise necessary to be internationally competitive in bioscience research. This infrastructure is supported and developed by our research community, including internationally recognized experts in life science and technology. The units and expertise create a unique environment for health and environmental research at the highest level. SciLifeLab started in 2010 as a joint effort between four universities: Karolinska Institutet, KTH Royal Institute of Technology, Stockholm University, and Uppsala University. Today, they support research activities at all major Swedish universities.

Scilife

Uppsala 05/10-2021

Navinci Diagnostics AB and Science for Life Laboratory, SciLifeLab, have entered a collaboration where the Naveni in situ Proximity Ligation Assay technique will be provided by the SciLifeLab unit Affinity Proteomics Uppsala

”We are delighted to partner with SciLifeLab and the Affinity Proteomics unit in Uppsala, as this allows the NaveniTM in situ proximity ligation assay technology to support the mission of SciLifeLab to enable life science research in Sweden to provide access to the latest key technologies. This collaboration will significantly benefit our academic customers that need help with assay development or sample analysis to support their research on protein interactions or signaling pathways. This is a natural continuation of the long-lasting close collaboration between Uppsala University, SciLifeLab, and Navinci.”
Robert Gunnarsson, CEO Navinci Diagnostics AB

”By implementing Navinci’s innovative products, we will be able to further strengthen our offering of in situ proximity ligation assay services by highly sensitive and reproducible assays. We are happy to continue a local and close relationship with companies with a legacy from Uppsala University.”
Mikael Åberg, Head of Affinity Proteomics Uppsala, SciLifeLab.

Founded upon the research by Ulf Landegren and colleagues at Uppsala University, Navinci (formerly known as Olink Bioscience) is a Swedish life science company that develops and markets in situ proximity ligation assays to monitor proteins, their interactions, and modifications. The technology provides an essential tool for spatial biology and reveals the responses to disease and drug treatment directly in the tissue microenvironment.
SciLifeLab leverages the unique strengths of individual researchers across Sweden into a focused resource for the life science community. SciLifeLab provides access for thousands of researchers to the cutting-edge instrumentation and deep scientific expertise necessary to be internationally competitive in bioscience research. This infrastructure is supported and developed by our research community, including internationally recognized experts in life science and technology. The units and expertise create a unique environment for health and environmental research at the highest level. SciLifeLab started in 2010 as a joint effort between four universities: Karolinska Institutet, KTH Royal Institute of Technology, Stockholm University, and Uppsala University. Today, they support research activities at all major Swedish universities.

Navinci partners with Oncolab GmbH, Austria, to supply reagents to their P53 Prions – A novel biomarker test for circulating tumor cells

Oncolab

Uppsala 24/9-2021

This innovative test from OncoLab (Austria) identifies cancer cells via p53 prions and is based on the proprietary proximity ligation technology from Navinci. The test kits can be used with tissues, cells, and blood.
This patent-pending new technology from Oncolab allows more reliable identification of circulating tumor cells (CTC). The technology is based on the detection of p53 aggregates (“p53 prions”) using blood-based biopsy tests (BBB) developed by OncoLab. p53 is a well-known tumor suppressor protein and mutations of the gene can cause prion-like aggregation of p53-proteins. OncoLab has developed tests for amplified immuno-labeling of these aggregates using proprietary technology of Navinci Diagnostics AB, a Swedish biotech company specializing in visualizing proteins, their protein-protein interactions and post-translational modifications.

“The p53 mutations can cause misfolding of the p53 protein leading to aggregation”, explains Prof. Zeillinger, CEO of OncoLab. “The misfolded proteins can act prion-like, also causing normal p53 proteins to bind to the aggregates. One of our tests can identify these aggregates in immobilized tissue sections or cells – another one in blood and other bodily fluids, allowing the identification of CTCs and DTCs (disseminated tumor cells) that often contain p53 aggregates.”
More than half of all cancer cells contain Tp53 mutations that may lead to misfolded proteins and aggregation. Identifying those aggregates can significantly improve the reliability of CTC identification as Prof. Zeillinger adds: “Most tests for identifying CTCs are based on detection of epithelial adhesion molecules (EpCAM) or cytokeratins. But not all CTCs express these biomarkers, and they are often downregulated during tumor progression. An additional marker, especially one expressed by a well-known tumor suppressor gene, is a highly desirable addition in the test kit market for CTCs, and we are very pleased to offer this novel assay for p53 prions.”

Besides p53 aggregates, the OncoLab’s CTC test “nPAC™ AMYLOplex™ CTC-p53” also detects known CTC markers (several cytokeratins) as well as leucocyte markers. It is based on immunofluorescence, which allows direct identification of CTCs and provides information about the morphology and numbers of CTCs. Immunofluorescence staining is also used in OncoLab’s “nPAC™ CRC IF” series of tests offered in collaboration with US-based AxonDx, LLC.
Further tests for other aggregated cancer proteins are under development at OncoLab, the first company to offer an extensive range of products for BBB based on either PCR or immunofluorescence. The development of the p53 prion test kits was a joint effort with the Swedish company Navinci that collaborates closely with Uppsala University.

Prof. Ulf Landegren of the Department of Immunology, Genetics and Pathology, Molecular Tools, comments: “Over recent years, my group has collaborated with Navinci to develop the necessary technologies for routine identification of aggregated tumor proteins. We are excited to now see the first kits hitting the market – and the potential for further tests is enormous.” Robert Gunnarsson, CEO Navinci Diagnostics AB comments: “As OncoLab has proven, the proximity ligation assay technique is ideal for studying aggregated tumor proteins, and we are thrilled that we together with OncoLab can provide novel tools to enhance the diagnosis of cancer and find better treatments.”

OncoLab brands the entire range of tests for aggregated proteins “AMYLOplex™.” The “AMYLOplex™ p53” test is available for research use (RUO), and a CE-IVD marked version for diagnostic purposes will be released within the following months.
As the first worldwide supplier of CTC test kits based on immunofluorescence and kits based on PCR, and now adding another first by offering the p53 prion test kits, OncoLab is regarded as one of the most innovative companies in the growing CTC/CRC diagnostic market. The complete product range of the company will be presented at the 5th ACTC – Advances in Circulation Tumor Cells meeting, 22nd – 25th of September, Kalamata, Greece.

Navinci Diagnostics AB and Lucerna-Chem AG have entered a distribution agreement for the Swiss market

Lucerna

Uppsala 24/9-2021

”The NaveniTM product line, which enables our customers to study the interplay of proteins in tissues and cells accurately, complements very well our broad portfolio of antibodies and research reagents. The Navinci team is dedicated to work closely with their customers and continue to innovate the field of spatial biology, which fits perfectly with our way of working.” – Adriano Tonini, COO Lucerna-Chem

“Switzerland is an important market for Navinci and Lucerna-Chem is an excellent organization for us to partner with as they have a strong presence in the region, customer base, and network. We much look forward to working closely with Lucerna-Chem to bring the NaveniTM proximity ligation assay kits to the Swiss life science research and pharma industry.” – Robert Gunnarsson, CEO Navinci Diagnostics AB.

Navinci partners with Biomol GmbH for the distribution of Naveni products in Germany

Biomol_Weiss_auf_Blau

Uppsala 15/6-2021

”Germany is an important market for Navinci and Biomol is a great organization for us to partner with. They are a highly skilled sales and marketing team that applies modern and forward-thinking methodologies. We look forward to working closely with Biomol to bring the NaveniTM proximity ligation assay kits to the German life science research and industry” says Robert Gunnarsson, CEO Navinci Diagnostics AB.

”With the addition of the NaveniTM product line to our broad portfolio of antibodies and research reagents, we enable our customers to specifically study the interplay of proteins in tissues and cells. Founded on the legacy as the original developer of the in situ proximity ligation assay, the Navinci team is dedicated to engaging with their customers to support and adapt to their needs, which resonates well with our way of doing business”  says Wilco van Hamond, CEO Biomol GmbH.

Navinci announces collaboration with Cambridge Bioscience in the UK and Ireland

Cambridge bioscience

Uppsala, 7/6-2021

Today we are pleased to announce our collaboration with Cambridge Bioscience to distribute Naveni products in the UK and Ireland!

”We are very pleased to partner with Cambridge Bioscience and their highly skilled sales and marketing team. Their long experience of serving customers in the life science research and industry will catalyze the accessibility of the NaveniTM proximity ligation assay kits in the UK and Ireland market.”
Robert Gunnarsson, CEO Navinci Diagnostics AB

”The Naveni products will be a great complement to our broad portfolio of antibodies and other research reagents, enabling our academic and pharma customers to study the interplay of proteins in tissues and cells. Navinci’s innovative products, combined with their expertise as the original developers of the proximity ligation technology, provides a good foundation for collaboration with our expert sales and support teams. Our aim is always to provide best-in-class solutions and support to our customers.”
Mike Kerins, Managing Director Cambridge Bioscience Limited